Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, Japan, July 20, 2009, Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it has established Astellas Farma Brasil...
Tokyo, Japan, July 13, 2009 - Astellas Pharma Inc. (“Astellas”; Headquarters: Tokyo; President and CEO: Masafumi Nogimori)today announced that the FAMOUS (Famotidine for the Prevention of Peptic U
Tokyo, Japan, July 7, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it was granted approval for moderately/severely...
Tokyo, Japan, July 1, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that Boehringer Ingelheim Pharmaceuticals, Inc....
Read more about ASTELLAS ANNOUNCES SUBMISSION OF PEDIATRIC DATA FOR FLOMAX® CAPSULES IN THE US
Tokyo, Japan, July 1, 2009 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori)today announced that Maxygen, Inc. (“Maxygen”; headquarters:...
Read more about Astellas Announces Joint Venture with Maxygen to Develop Protein Pharmaceuticals
Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo: Chairman & President: Dr. Thomas Heil) and Astellas Pharma Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi...
Tokyo, Japan/June 17, 2009 - Astellas Pharma Inc. (“Astellas”; Headquarters: Tokyo; President and CEO: Masafumi Nogimori) and Pfizer Japan Inc. (“Pfizer”; Headquarters: Tokyo; President...
Japan, June 2, 2009 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter “Astellas”)today announced that the prevention of peptic ulcers in uses of...
Japan, May 13, 2009 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called the “the Company”) today announced that at the meeting of the Board of...
Japan, May 13, 2009 – Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter called “the Company”) today announced that at the meeting of the Board of...
Read more about Astellas Announces Cancellation of Treasury Stock
Japan, April 27, 2009 - Astellas Pharma Inc. ("the Company"; headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced that it has decided to nominate two candidates of outside...
Nippon Boehringer Ingelheim Co., Ltd. (Headquarters: Shinagawa-ku, Tokyo: Chairman & President: Dr. Thomas Heil) and Astellas Pharma Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Masafumi...
Read more about MICOMBI® Combination Tablets approved for manufacturing and marketing
Japan, April 7, 2009 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) today announced that it has decided to construct Fermentation Technology...
Japan, April 6, 2009 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc. (“Astellas”; headquarters:...
Read more about Launch of the Osteoporosis Treatment, RECALBON® Tablets / Bonoteo® Tablets
Tokyo, Japan, March 16, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that it will terminate its $16.00 per share offer for CV Therapeutics, Inc. (Nasdaq: CVTX) and will not...
Read more about ASTELLAS TO TERMINATE OFFER FOR CV THERAPEUTICS
Tokyo, Japan, March 6, 2009 – Astellas Pharma Inc. today announced that its wholly owned subsidiary, Astellas US Holding, Inc., will nominate two directors for election to the Board of Directors...
Japan, March 3, 2009 - Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori, hereinafter “Astellas”) today announced that Astellas has terminated the License...
Read more about Astellas Terminates Agreement on Antipsychotic Agent ASP2314/ACR-16
TOKYO, JAPAN and SANTA CLARA, CA- March 2, 2009 - Astellas Pharma Inc. (Astellas) and XenoPort, Inc. (NASDAQ: XNPT) today announced preliminary top-line results from a Phase 2 clinical trial of...
Tokyo, Japan, February 27, 2009 – Astellas US Holding, Inc., a wholly owned subsidiary of Astellas Pharma Inc., today announced that it has filed a lawsuit in the Delaware Chancery Court against...
Read more about ASTELLAS FILES LAWSUIT AGAINST CV THERAPEUTICS
Tokyo, Japan, February 27, 2009 – Astellas Pharma Inc. (“Astellas”) today announced that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced a cash tender offer for all...
Tokyo, Japan, February 23, 2009 – Astellas Pharma Inc. (“Astellas”) today commented on CV Therapeutics, Inc’s. (Nasdaq: CVTX) announcement that its Board of Directors has rejected...
Follow us
